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Background: Women who have had small for gestational age offspring have an 
increased risk of cardiovascular disease in later life. Endothelial dysfunction is a 
subclinical sign of early cardiovascular disease. It is unknown whether women who 
have recently had a pregnancy complicated by fetal growth restriction, in the 
absence of other maternal and fetal disease, have subclinical endothelial 
dysfunction.  
Objective: To assess maternal endothelial function six months after a pregnancy 
complicated by fetal growth restriction. 
Methods: This was a case-control study, conducted in a tertiary referral hospital in 
London over a 15-month period. Flow-mediated dilatation (FMD) of the brachial 
artery was measured in women, six months (+/- 2.5 months) after the birth of their 
child.  Forty-four women were studied; 15 had a growth restricted offspring 
(customised birth centile 1.9 ± 2.3; mean ± SD) and 29 women had delivered an 
appropriately grown baby (customized birth centile 47.5 ± 26.3).  Results were 
analysed using an unpaired t-test and the means of the primary continuous variable 
(FMD % change).  
Results: Women who had a growth restricted offspring had lower postpartum FMD 
(6.79% ± 0.95%) compared with mothers who had an appropriately grown offspring, 
FMD 10.26% ± 2.44%; 95% CI -5.37 to -1.57 (p=0.0007;). There were no differences 
in postnatal measures of maternal blood pressure, abdominal circumference, weight, 







Conclusions: Within six months of childbirth, women who have had a pregnancy 
affected by fetal growth restriction due to likely placental failure, but in the absence 
of pre-eclampsia, have evidence of subclinical endothelial dysfunction. These 
women may benefit from lifestyle measures focused on the primary prevention of 
cardiovascular disease. Further research, with larger populations, is needed to 
discover whether this postpartum maternal endothelial dysfunction is a pregnancy-
induced phenomenon, or related to pre-existing maternal phenotype and indeed 






















Endothelial dependent flow mediated dilation (FMD) is a non-invasive way to assess 
vascular function.1 By measuring the change in brachial artery diameter in response 
to increased blood flow, endothelial function can be assessed contemporaneously.2 
Women, who have experienced pre-eclampsia, are at increased risk of 
cardiovascular disease.3 Subclinical endothelial dysfunction is evident within 6 
months of a woman having a pregnancy affected by pre-eclampsia, demonstrated 
through lower flow mediated dilation.4   
Women who have had a baby in the lowest birth-weight quintile for gestational age, 
as well as those who delivered a small-for-gestational age (SGA) infant (independent 
of other recognised risk factors) have an increased lifetime risk of ischaemic heart 
disease (IHD).5 This risk is dose dependent, varying according to severity of SGA 
and previous number of SGA pregnancies.6 It is less clear whether early impaired 
endothelial dysfunction is present in women who have delivered a growth restricted 
infant.  
As pregnancy progresses, high resistance maternal uterine arteries are transformed 
into low resistance, high capacitance vessels to facilitate the provision of oxygen and 
nutrients, for placental development and optimal fetal growth. Dysfunction within the 
placenta is thought to a central component of both pre-eclampsia and fetal growth 
restriction.7 It is possible that aberrant remodelling of the utero-placental circulation 
resulting in a growth restricted fetus might be influenced by underlying maternal 
vascular phenotype or conversely, compromised placental development may itself 






contemporaneously investigate women who had a pregnancy complicated by fetal 
growth restriction, independent of other maternal and fetal disease, hypothesising 
that they would have impaired endothelial function evident shortly after an affected 
pregnancy, similar to that seen in pre-eclampsia. 
Given that subclinical endothelial dysfunction is a prelude to the later development of 
cardiovascular disease8,9 and brachial artery FMD is inversely correlated with future 
cardiovascular events,10 then identification, using FMD, of a cohort of women, with 
post-partum sub-clinical endothelial dysfunction would provide a novel way of 
identifying women at future risk of cardiovascular disease. This finding then 
has the potential to prevent or ameliorate disease in these women through 
personalised lifestyle adjustments and monitoring.  
METHODS 
This was a case control study undertaken at the Clinical Research Facility, University 
College London Hospital (UCLH). Ethical approval for this study was granted by the 
Joint UCLH/UCL (alpha) Ethical Committee (09/H0715/28).  
Couples were recruited antenatally, over a 15month period. Recruitment took place 
in the antenatal period to give time for couples to consider the study and to consent 
to collection of fetal samples after delivery. Eligible participants were approached in 
a range of hospital settings, as has been described in our previous publication.11  
Fetal growth restriction (FGR) was identified by ultrasound and was defined as an 
antenatal customised birth weight less than the 10th centile.12 All cases of FGR were 






were excluded. We also excluded women who smoked, who also developed pre-
eclampsia or who had gestational hypertension (>140/90mmHg) to best elicit 
placentally derived growth restriction, independent of the effect of pre-eclampsia.  
Pregnant women were recruited as controls, at the same time point and from the 
same clinical area, as cases, if they were thought to be having a normally grown 
baby with an estimated fetal weight between 10th and 95th customised centile as 
assessed by an antenatal ultrasound and which was confirmed by postnatal 
assessment. Only non-smoking women who did not develop pre-eclampsia or 
gestational hypertension were included as controls or cases, in order to try and 
minimize confounding influences of extrinsic maternal factors. 
Each parent also completed a questionnaire enquiring about past medical, family 
and treatment history. Own birth weight was remembered personally, or from a 
parent. Maternal antenatal notes were reviewed to provide pertinent antenatal data. 
Women were invited back for postpartum study, by letter, email or telephone 
between four months and one year after the birth of their child, after breastfeeding 
had ceased, on a day when not menstruating. The study room was temperature 
controlled at 24oC. Participants were asked to fast overnight for at least 10h before 
study and all postnatal studies were performed in the morning. Weight, height and 
abdominal circumference were recorded. After resting, two measures of supine 
blood pressure (BP) were taken 15 minutes apart. The same single trained operator 
measured blood pressure by auscultatory sphygmomanometry, using an aneroid 






to arm circumference. The mean value of two separate measurements 15 minutes 
apart was used for analysis.  
Fasting venous insulin, glucose and lipid levels were measured. Insulin resistance 
(IR) was calculated using the HOMA model.13 Blood was spun within 1hr of 
venepuncture and plasma and serum were frozen at -80oC. All blood samples were 
processed in the same laboratory.  
Endothelial function was assessed using brachial artery flow-mediated dilatation 
(FMD). A single operator, trained and validated within an established group 
using FMD14, performed the scans, using established protocols as previously 
reported for conducting flow-mediated dilatation.14 Briefly, the right arm was 
rested in an arm holder and the forearm was raised slightly using a foam pad. An 
8.5cm wide pneumatic cuff was then placed around the upper forearm, 2cm distal to 
the medial epicondyle (figure 1).  
Cuff pressure inflation was controlled by an automatic cuff inflator (Hokanson Cuff 
Inflator, PMS Instruments Ltd, Maidenhead, UK). Using an ultrasound probe in the 
longitudinal plane, a segment of brachial artery was identified and studied before and 
after a five-minute compressive arterial occlusion. 
An Aloka SSD 5000 ultrasound machine was used with a 13MHz linear array 
transducer probe (Aloka Holding Europe, AG Switzerland). The image was acquired 
in B-mode and the probe fixed so that a 5-10cm segment of the brachial artery 
proximal to the antecubital fossa was in view. Longitudinal end diastolic images, in 
conjunction with ECG tracing were acquired every three seconds during the eleven 






and five minutes with cuff deflated). Blood flow velocity was continuously monitored 
during the scan by switching to a B/D (Doppler) mode for the test duration. 
Images were acquired and analysed using automated software (Brachial Tools 
Medical Imaging Applications, Iowa, USA). With the initial segment recorded a 
smaller region of maximum clarity was selected for analysis. To provide internal 
reproducibility two different segments within each scan were analysed and compared 
for similarity. Stringent inclusion criteria were applied. Analysis exclusion criteria 
included; poor image quality, if recording was deemed to be unrepresentative of the 
true vessel diameter or if the image did not return to near baseline after reperfusion.  
Each image-recording was validated by a second operator blinded to the subject’s 
group. FMD was calculated as a percentage change from baseline brachial artery 
diameter (mm) to maximum dilation (mm) after reperfusion, using semi automated 
continuous capture software. Scans were excluded if the FMD results from two 
different segments or second operator validation differed by >1.5%.   
Statistical Analysis 
Cases and controls were assessed for comparability with simple descriptive 
statistics.  Baseline antenatal characteristics of cases and controls are summarised 
with means and standard deviations (SD). Postnatal measurements are summarised 
with means and SD. For continuous variables, 95% confidence limits are given and 
percentages for categorical variables, e.g. sex. Statistical analysis was carried out 
using STATA 10 (StataCorp LP, Texas USA) and GraphPad Prism version 5. Visual 
assessment of normality curves for variables was undertaken to assess for 






primary continuous variable (FMD % change). Two tailed P-values <0.05 were 
considered statistically significant.  
 
RESULTS 
Recruitment occurred over a 15-month period. Women were invited back by 
telephone, email or letter. Eight could not be contacted due to out of date details or 
no response. Of the 94 women contacted, 61 (65%) were studied in the 
postnatal period. Of those women not studied; 8 were pregnant at the time of 
recall; 10 women declined to come back having moved area or having been 
out of area initially and 15 women declined due to work or family 
commitments.  
 
In total, 24 women who had pregnancies affected by fetal growth restriction (FGR; 
cases) and 37 women who had an appropriately growth baby (AGA; controls) were 
able to attend postnatal appointments. Of FGR cases, 4 women also experienced 
pre-eclampsia so were excluded from final analysis. After quality checks of FMD 
recordings (as described in the methods section), 13 studied were excluded; 8 
controls and 5 cases. Four studies (2 cases and 2 controls) were excluded 
because 2nd operator value varied >1.5%; 5 further studies (3 controls, 2 cases) 
were rejected as the baseline did not return by the end of the recording; in 2 
control studies the recording not completed and the recording was rejected 
due to image quality in 2 studies (1 case and 1 control). Thus, 29 studies of 
postnatal FMD scans on mothers with AGA offspring were eligible for analysis 







Baseline characteristics of these 44 offspring confirmed that case and control 
offspring subjects met the study criteria. In cases, mean customised birth weight 
centile was 1.9th (± 2.3) with a mean birth weight of 2254g (± 547g) and gestation of 
268 days (± 19.4 days). The mean customised birth centile of controls was 47.5th (± 
26.3) centile with a mean birth weight of 3566g (± 350g) and gestation of 285 days 
(±9.6 days).  
Maternal pre-pregnancy age, weight (kg), height (cm) and parity revealed no 
differences between cases and controls (table 1). There was no difference between 
the groups in BP at 10-12 weeks gestation, no women in either group developed 
sustained hypertension >140/90mmHg before childbirth or peripartum. Maternal BP 
at time of FMD study remained similar (table 2).  
Antenatally and peripartum, and no women reported pre-pregnancy hypertension or 
significant medical conditions. 
Postnatal study was carried out at 6.9 ± 2.5 months after the birth of their baby 
(mothers of AGA offspring) and at 6.8-± 2.5 months post-partum (mothers of FGR 
offspring) (p=0.92 95% CI -1.537 to 1.690). Postpartum, there was no difference 
between case and control women in relation to maternal weight, waist circumference 
or blood pressure (table 2). More mothers of FGR pregnancies had a caesarean 
section 63.9% compared with 27% mothers of AGA offspring.  
Women whose pregnancy had been complicated by FGR had lower FMD 
(6.79±0.95%) compared with women who had an appropriately grown baby (FMD 






Postpartum fasting glucose and insulin levels were similar between control and case 
mothers, which reflected no difference in insulin resistance, as defined by the 
HOMA-IR index. There were also no differences in lipid profile, renal function, 25 
(OH) D, B12, or folate levels between cases and controls.  
DISCUSSION 
Principal Findings of the Study  
In healthy individuals, flow mediated dilatation has been reported to range from 8-
15%.2 The data generated by this study supports the concept that impaired 
endothelial function is present postnatally in women who have had pregnancies 
affected by growth restriction. Fetal growth restriction, like pre-eclampsia, might 
be acting as a maternal ‘stressor’ triggering a pre existing underlying maternal 
vascular phenotype.  
To avoid the influence of known risk factors for endothelial dysfunction, women who 
had chronic diseases, pre-eclampsia or who smoked and those mothers who were 
still breast-feeding were excluded from analysis. Given this, then it is also 
possible that compromised placental development may itself be influencing 
future maternal vascular health. 
Comparison with findings of previous studies 
Maternal endothelial dysfunction is known to be impaired during and after a 
pregnancy complicated by pre-eclampsia.15, 16 We found very similar FMD 
measurements in mothers who had pregnancies affected by FGR as were found 






7.3±2.4%).16 Large-scale retrospective population studies have shown that women 
who have had an SGA baby have an increased risk of IHD. 5,6,17 It was been reported 
that within 4 years, a woman who experiences a pregnancy affected by growth 
restriction, exhibits worse endothelial function and metabolic profiles than a control 
population.18, 19 However, in one study, maternal blood pressures were higher during 
pregnancies affected by SGA and the postpartum study period compared with 
women who had AGA offspring. In our study, maternal blood pressures were similar 
at booking and during labour between FGR and AGA pregnancies.  
Women in our study were asymptomatic without marked metabolic dysfunction, yet 
had sub-clinical endothelial dysfunction; a recognised prelude to metabolic syndrome 
and cardiovascular disease, soon after a growth restricted pregnancy. A meta-
analysis of 14 prospective studies has revealed that the risk of a cardiovascular 
event is reduced by 13% for every 1% increase in FMD.20  
 
Limitations of the study 
We included well phenotyped cases of fetal growth restriction, but the postnatal 
study was carried out six months after initial recruitment, with stringent exclusion 
criteria. A limitation of this study was the loss (~40%) to follow up, of antenatal 
participants recruited. However, when analysed, drop out rates and reasons 
for non-attendance were similar in both groups, likely limiting any bias effect. 
We found that women who had FGR, had a 3.47% lower FMD than mothers of AGA 






cardiovascular risk between the groups, it is possible that the association between 
FMD and CV disease is not as strong in asymptomatic populations.21 Due to 
stringent exclusion criteria, a number of FMD results were rejected. The 
number rejected due to 2nd operator disagreement was only ~6%, which is 
consistent with previously published data22 but the overall number of studied 
rejected due to additional criteria is higher. Given the number of exclusions 
caution in interpreting results is appropriate. However, a sub-analysis of 
rejected images and pre-eclamptic subjects did not alter the overall finding of 
lower FMD in case women. FMD values can vary according to a number of 
environmental factors such as; time of day, food consumption and phase of the 
menstrual cycle.1 Whilst we tried to account for these factors they may be 
confounding the result. A bigger longitudinal cohort, replicating these initial results, 
would strengthen the association identified and is planned as part of a follow on 
study.  
Implications for Practice 
The pathophysiological pathway by which poor placental function with FGR, in the 
absence of maternal gestational hypertension/pre-eclampsia, is associated with 
maternal endothelial dysfunction is yet to be elucidated. A prospective study of 
pregnancy outcomes, with preconception and postnatal measures of maternal FMD 
in the same women, would elucidate the role of pregnancy-induced endothelial 
dysfunction. Reproducibility of the technique, as evidenced with this study, 
along with its high operator dependency, are issues that need to be taken into 






being considered.  
Longitudinal follow up could also elicit whether decreased FMD persists in these 
individuals as there is some evidence to suggest FMD changes can resolve after 10 
years.23, 24 
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Table 1. Maternal endothelial function in growth restriction 
Maternal Antenatal Baseline characteristics at 10-12 weeks gestation and 







 n= 15   Mothers         
with AGA 
n=29  
 Mean SD Min Max Mean SD Min Max 
Age (years) 33.2 3.3 20 40 32.6 3.7 20 39 
Weight (kg) 60.0 7.8 48 80 64.1 10.7 44 84 
Height (cm) 164.5 5.3 152 175 166.0 6.1 156 185 
Booking BMI  
(kg/m2) 











































































(-10.2 to 5.05) 
Waist Circumference (cm) 81.9 (6.7) 82.9 (6.5) 0.76 (-7.63 to 5.66) 
Systolic BP (mmHg) 105.6 (13) 109.1 (7.9) 0.15 (-8.45 to 1.31) 
Diastolic BP (mmHg) 64.0 (7.68) 63.9 (7.68) 0.98 (-3.68 to 3.80) 
FMD (%)  6.79 (0.95) 10.26 (2.44) 0.0007 (-5.37 to -1.57) 
 
Table 2. Maternal endothelial function in growth restriction 
















Table 1. Baseline characteristics of mothers with FGR offspring (<10th customised 
birth weight centile: n=15) compared with mothers who had AGA offspring (10th - 95th 
customised birth weight centiles; n=29). Assessment at 10-12 weeks gestation 
including; age (years), weight (kg) at first booking visit, height, body mass index 
(BMI) kg/m2, recorded blood pressure in antenatal clinic (mmHg) (sitting and by 
same operator) and parity of the women.  
 
Table 2. Physical measurements of the 29 women with AGA offspring originally 
recruited and 15 women who had FGR offspring studied at 6.8 ± 2.5 months.  
Measurements included weight (kg), height (cm), abdominal circumference (cm) and 
blood pressure (mmHg), and revealed no significant differences. Flow mediated 
dilatation (FMD), as expressed as % change from baseline, was significantly 
different between cases and controls.  
 
FIGURE LEGENDS 
Figure 1: Flow mediated dilatation equipment. Image shows configuration of the 
equipment necessary to record the diameter of the brachial artery.  
 
